Stimulation of collateral artery growth: Travelling further down the road to clinical application

Heart

Volumn 95, Issue 3, 2009, Pages 191-197

  Schirmer, S H ^a   Van Nooijen, F C ^a   Piek, J J ^a   Van Royen, N ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; FIBROBLAST GROWTH FACTOR 2; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN DEL1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTERY ENDOTHELIUM; CELL PROLIFERATION; CLINICAL TRIAL; COLLATERAL ARTERY GROWTH; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; SMOOTH MUSCLE FIBER;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COLLATERAL CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMORHEOLOGY; HUMANS; MALE; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 62149099949     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2007.136119     Document Type: Review

References (92)

1. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992;327:1825-31.
2. Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals, a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007;116:975-83.
3. Seiler C. The human coronary collateral circulation. Heart 2003;89:1352-7.
4. Schaper J, Konig R, Franz D, et al. The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes. A combined SEM and TEM study. Virchows Arch A Pathol Anat Histol 1976;370:193-205.
5. Fulton WF. Arteriel anastomoses in the coronary circulation. I. Anatomical featues in normal and diseased hearts demonstrated by stereoarteriography. Scoff Med J 1963;143:420-34.
6. Wustmann K, Zbinden S, Windecker S, et al. Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation 2003;107:2213-20.
7. Ito WD, Arras M, Scholz D, et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol 1997;273:H1255-65.
8. Gray C, Packham IM, Wurmser F, et al. Ischemia is not required for arteriogenesis in zebrafish embryos. Arterioscler Thromb Vasc Biol 2007;27:2135-41.
9. Shyy JYJ, Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002;91:769-75.
10. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 2007;454:345-59.
11. Scholz D, Schaper W. Preconditioning of arteriogenesis. CardiovascRes 2005;65:513-23.
12. Hoefer IE, van Royen N, Buschmann IR, et al. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 2001;49:609-17.
13. Eitenmuller I, Volger O, Kluge A, et al. The range of adaptation by collateral vessels after femoral artery occlusion. Circ Res 2006;99:656-62.
14. Prera D, Kanaganayagam GS, Saha M, et al. Coronary collaterals remain recruitable after percutaneous intervention. Circulation 2007;115:2015-21.
15. Zimarino M, Ausiello A, Contegiacomo G, et al. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol 2006;48:59-65.
16. Werner GS, Emig U, Mutschke O, et al. Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings. Circulation 2003;108:2877-82.
17. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). CircRes 2004;95:449-58.
18. Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998;101:40-50.
19. Grundmann S, Hoefer I, Ulusans S, et al. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit. Am J physiol 2005;289:H1497-505.
20. Hoefer IE, Grundmann S, Schirmer S, et al. Aspirin, but not clopidogrel, reduces collateral conductance in a rabbit model of femoral artery occlusion. J Am Coll Cardiol 2005;46:994-1001.
21. van Royen N, Voskuil M, Hoefer I, et al. CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization. Circulation 2004;109:1647-52.
22. Bergmann CE, Hoefer IE, Meder B, et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol 2006;80:59-65.
23. Hoefer IE, Grundmann S, van Royen N, et al. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis 2005;181:285-93.
24. Stabile E, Burnett MS, Watkins C, et al. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 2003;108:205-10.
25. Stabile E, Kinnaird T, la Sala A, et al. CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation 2006;113:118-24.
26. Wolf C, Cai WJ, Vosschulte R, et al. Vascular remodeling and altered protein expression during growth of coronary collateral arteries. J Mol Cell Cardiol 1998;30:2291-305.
27. Carr AN, Howard BW, Yang HT, et al. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: support for an endothelium-dependent mechanism. Cardiovasc Res 2006;69:925-35.
28. Cai W, Vosschulte R, Afsah-Hedjri A, et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 2000;32:997- 1011.
29. Cheng XW, Kuzuya M, Nakamura K, et al. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res 2007;100:904-13.
30. Schirmer SH, Buschmann IR, Jost MM, et al. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis. Cardiovasc Res 2004;64:356-64.
31. Voskuil M, van Royen N, Hoefer IE, et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol 2003;284:H1422-8.
32. van Royen N, Hoefer I, Buschmann I, et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. CardiovascRes 2003;57:178-85.
33. van Royen N, Hoefer I, Bottinger M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003;92:218-25.
34. Deindl E, Zaruba MM, Brunner S, et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 2006;20:956-8.
35. Buschmann IR, Hoefer IE, van Royen N, et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001;159:343-56.
36. Grundmann S, Hoefer I, Ulusans S, et al. Granulocyte-macrophage colonystimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps. J Vasc Surg 2006;43:1263-9.
37. Buschmann IR, Busch HJ, Mies G, et al. Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor. Circulation 2003;108:610-5.
38. Wiseman DM, Polverini PJ, Kamp DW, et al. Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988;157:793-800.
39. Boengler K, Pipp F, Fernandez B, et al. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). CardiovascRes 2003;59:573-81.
40. van Royen N, Hoefer I, Buschmann I, et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002;16:432-4.
41. Grundmann S, van Royen N, Pasterkamp G, et al. A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-[beta]1 release. J Am Coll Cardiol 2007;50:351-8.
42. Fujii T, Yonemitsu Y, Onimaru M, et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vase Biol 2006;26:2483-9.
43. Wu HM, Yuan Y, McCarthy M, et al. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am J Physiol 1996;271:H1087-93.
44. Ueno H, Li JJ, Masuda S, et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997;17:2453-60.
45. Srivastava S, Terjung RL, Yang HT. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart C/rcPhysiol 2003;285:H1190-7.
46. Rissanen TT, Markkanen JE, Arve K, et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 2003;17:100-2.
47. Crottogini A, Meckert PC, Vera Janavel G, et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum Gene Ther 2003;14:1307-18.
48. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-89.
49. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003;92:378-85.
50. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
51. Hoefer IE, van Royen N, Rectenwald JE, et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation 2002;105:1639-41.
52. Gluzman Z, Koren B, Preis M, et al. Endothelial cells are activated by angiopoeitin-1 gene transfer and produce coordinated sprouting in vitro and arteriogenesis in vivo. Biochem Biophys Res Commun 2007;359:263-8.
53. Siddiqui AJ, Blomberg P, Wardell E, et al. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophy sRes Commun 2003;310:1002-9.
54. Schirmer SH, Royen NV. Stimulation of collateral artery growth: a potential treatment for peripheral artery disease. Expert Rev Cardiovasc Ther 2004;2:581-9.
55. Henry TD, Annex BH, McKendall GR, et al. The VIVA Trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65.
56. Rajagopalan S, Mohler ER, III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-9.
57. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
58. Lederman RJ, Mendelsohn F0, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8.
59. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocytemacrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001;104:2012-7.
60. van Royen N, Schirmer SH, Atasever B, et al. START Trial: a pilot study on Simulation of ARTeriogenesis using subcutaneous application of granulocytemacrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005;112:1040-6.
61. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153:874-80.
62. Belardinelli R, Belardinelli L, Shryock JC. Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy. Eur Heart J 2001;22:1205-13.
63. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
64. Zbinden S, Zbinden R, Meier P, et al. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1636-42.
65. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21.
66. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-32.
67. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-209.
68. Erbs S, Linke A, Schachinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 2007;116:366-74.
69. Zbinden R, Zbinden S, Meier P, et al. Coronary collateral flow in response to endurance exercise training. Eur J Cardiovasc Prev Rehabil 2007;14:250-7.
70. Helisch A, Wagner S, Khan N, et al. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol 2006;26:520-6.
71. van Weel V, de Vries M, Voshol PJ, et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol 2006;26:1383-90.
72. Epstein SE, Stabile E, Kinnaird T, et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004;109:2826-31.
73. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
74. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation 1999;99:111-20.
75. Reed MJ, Bradshaw AD, Shaw M, et al. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age. J Cell Physiol 2005;204:800-7.
76. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol 2001;38:1872-8.
77. Zeiher AM, Drexler H, Saurbier B, et al. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-62.
78. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003;42:2073- 80.
79. Piek JJ, Koolen JJ, Hoedemaker G, et al. Severity of single-vessel coronary arterial stenosis and duration of angina as determinants of recruitable collateral vessels during balloon angioplasty occlusion. Am J Cardiol 1991;67:13-7.
80. Werner GS. Collaterals: how important are they? Heart 2007;93:778-9.
81. Bondke A, Hillmeister P, Buschmann IR. Exact assessment of perfusion and collateral vessel proliferation in small animal models. Circ Res 2007;100:e82-3.
82. Seiler C. Role (of assessment) of the human collateral circulation in (characterizing) ischemic adaptation to repeated coronary occlusion. J Am Coll Cardiol 1998;31:1698-9.
83. van Liebergen RA, Piek JJ, Koch KT, et al. Quantification of collateral flow in humans: a comparison of angiographic, electrocardiographic and hemodynamic variables. J Am Coll Cardiol 1999;33:670.
84. Perera D, Patel S, Blows L, et al. Pharmacological vasodilatation in the assessment of pressure-derived collateral flow index. Heart 2006;92:1149-50.
85. Vogel R. Zbinden R, Indermuhle A, et al. Collateral-flow measurements in humans by myocardial contrast echocardiography: validation of coronary pressure-derived collateral-flow assessment. Eur Heart J 2006;27:157-65.
86. Pascotto M. Wei K, Micari A, et al. Phasic changes in arterial blood volume is influenced by collateral blood flow: implications for the quantification of coronary stenosis at rest. Heart 2007;93:438-43.
87. Muehling OM, Huber A, Cyran C, et al. The delay of contrast arrival in magnetic resonance first-pass perfusion imaging: a novel non-invasive parameter detecting collateral-dependent myocardium. Heart 2007;93:842-7.
88. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drugeluting stent implantation. J Am Coll Cardiol 2007;49:15-20.
89. Chittenden TW, Sherman JA, Xiong F, et al. Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation 2006;114:1811-20.
90. Schirmer SH, Hoefer IE, Fledderus JO, et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008;102:1268-94.
91. Perera D, Postema P, Rashid R, et al. Does a well developed collateral circulation predispose to restenosis after percutaneous coronary intervention? An intravascular ultrasound study. Heart 2006;92:763-7.
92. Jensen LO, Thayssen P, Lassen JF, et al. Recruitable collateral blood flow index predicts coronary instent restenosis after percutaneous coronary intervention. Eur Heart J 2007;28:1820-6.